Edition:
United States

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.67USD
2:22pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.67
Open
$1.67
Day's High
$1.69
Day's Low
$1.67
Volume
219,632
Avg. Vol
211,850
52-wk High
$2.62
52-wk Low
$1.02

Latest Key Developments (Source: Significant Developments)

Athersys reports Q3 loss per share $0.06
Wednesday, 8 Nov 2017 04:03pm EST 

Nov 8 (Reuters) - Athersys Inc :Athersys reports third quarter 2017 results.Q3 loss per share $0.06.Q3 revenue $400,000 versus $300,000.Q3 revenue view $598,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Athersys and Nikon Cell Innovation to collaborate on MultiStem manufacturing in Japan
Wednesday, 11 Oct 2017 06:00am EDT 

Oct 11 (Reuters) - Athersys Inc ::Athersys and Nikon Cell Innovation to collaborate on multistem commercial manufacturing in Japan.Athersys - entered manufacturing services agreement with Nikon Cell for commercial production of its stem cell therapy in Japan for ischemic stroke.Athersys - technology transfer of stem cell production methods in preparation for potential commercialization in Japan after treasure clinical study.  Full Article

Athersys Q2 loss per share $0.06
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Athersys Inc :Athersys reports second quarter 2017 results.Q2 revenue $700,000 versus $600,000.Q2 loss per share $0.06.Q2 revenue view $554,000 -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S.  Full Article

Athersys reports alignment of key regulators for pivotal registration study in stroke
Monday, 7 Aug 2017 06:00am EDT 

Aug 7 (Reuters) - Athersys Inc :Athersys reports alignment of key regulators for pivotal registration study in stroke.Athersys Inc - in Japan, Athersys' partner, Healios K.K. is conducting treasure study, evaluating multistem therapy for ischemic stroke.Athersys - design of phase 3 clinical study treating ischemic stroke with multistem cell therapy product received a final scientific advice positive opinion from EMA.Athersys - treasure study has received a priority review designation under Sakigake from Japan's pharmaceutical and medical devices agency.Athersys - results from treasure study are acceptable for supporting applications for registration, along with results from masters-2 study, in U.S., Europe.  Full Article

Athersys reports Q1 loss per share $0.06
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Athersys Inc :Athersys reports first quarter 2017 results.Q1 revenue $1.5 million versus $15.5 million.Q1 loss per share $0.06.Q1 revenue view $638,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S.  Full Article

Athersys Inc files for mixed shelf offering of up to $75 mln
Friday, 10 Mar 2017 05:49pm EST 

Athersys Inc :Athersys Inc files for mixed shelf offering of up to $75 million - sec filing.  Full Article

Athersys reports pricing of public offering of common stock
Friday, 27 Jan 2017 09:00am EST 

Athersys Inc :Athersys announces pricing of public offering of common stock.  Full Article

Athersys announces proposed public offering of common stock
Thursday, 26 Jan 2017 04:28pm EST 

Athersys Inc : Announces proposed public offering of common stock . Intends to offer for sale shares of its common stock, par value $0.001 per share .Intends to use net proceeds for working capital and general corporate purposes, funding towards its phase 3 multistem administration, among others.  Full Article

Athersys, FDA agree on design for ischemic stroke late-stage study
Wednesday, 28 Sep 2016 06:30am EDT 

Athersys Inc :Athersys receives FDA agreement under special protocol assessment for phase 3 study of multistem® treatment for ischemic stroke.  Full Article

Athersys qtrly loss per share $0.08
Tuesday, 9 Aug 2016 04:03pm EDT 

Athersys Inc : Athersys reports second quarter 2016 results . Q2 revenue $600,000 versus $200,000 .Qtrly loss per share $0.08.  Full Article

BRIEF-Athersys reports Q3 loss per share $0.06

* Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: